David S Hong, MD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
In the News
Novel T cell receptor therapy shows early anti-tumor activity
How Therapeutics Discovery is developing targeted therapies for more cancer types
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
ASCO: Emerging targeted therapies show signs of clinical activity across multiple cancer types
Q&A: Phase I clinical trials
Larotrectinib shows marked responses with NTRK gene fusions, limited response in non-fusion mutations
Present Title & Affiliation
Primary Appointment
Deputy Chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Phase I studies Drug development The molecular basis of cancer
Click here for the most up-to-date list of Dr. Hong's publications.
Education & Training
Degree-Granting Education
| 1999 | Albert Einstein College of Medicine, New York, NY, USA, MD, Medicine |
| 1993 | Yale University, New Haven, CT, USA, BS, Oncology |
Postgraduate Training
| 2004-2004 | Rotation, NCI-CTEP, Bethesda, MD |
| 2002-2005 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1999-2001 | Clinical Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA |
Board Certifications
| 2007 | Medical Oncology |
| 2002 | Internal Medicine |
Grant & Contract Support
| Title: | Targeted Therapy Program; Cancer Center Support (Core) Grant |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader (2013-2014) |
Patient Reviews
CV information above last modified August 08, 2024